[The application of non-selective β-blockers, angiotensin receptor antagonists and statins in liver cirrhotic patients]

Zhonghua Gan Zang Bing Za Zhi. 2019 Dec 20;27(12):923-928. doi: 10.3760/cma.j.issn.1007-3418.2019.12.004.
[Article in Chinese]

Abstract
in English, Chinese

Portal hypertension is the major cause of complications in decompensated liver cirrhosis. Research results showed that non-selective β-blockers, angiotensin receptor antagonists, and statins can improve portal hypertension by reducing portal vein blood flow and intrahepatic resistance, and have certain prevention and treatment effect on hemodynamic disorders and portal hypertensive complications in chronic liver diseases. Herein, we review the mechanism of action, clinical effects and limitations of these three types of drugs on portal hypertension of cirrhosis.

门静脉高压是肝硬化失代偿期并发症产生的主要病因。有研究结果显示非选择性β-受体阻滞剂、血管紧张素受体拮抗剂及他汀类药物可通过减少门静脉血流、降低肝内血管阻力改善肝硬化引起的门静脉高压，对慢性肝病引起的血流动力学紊乱、门静脉高压并发症有一定的防治作用。现就这3类药物对肝硬化门静脉高压的治疗作用的机制、临床效果及局限性加以阐释。.

Keywords: Angiotensin receptor antagonists; Liver cirrhosis; Non-selective β-blockers; Portal hypertension; Statins; Therapy.

Publication types

  • Review

MeSH terms

  • Angiotensin Receptor Antagonists / therapeutic use*
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Hypertension, Portal / drug therapy
  • Hypertension, Portal / etiology*
  • Hypertension, Portal / physiopathology
  • Liver Cirrhosis / complications
  • Liver Cirrhosis / drug therapy*

Substances

  • Angiotensin Receptor Antagonists
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors